AegirBio AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 0.001 million. Net loss was SEK 16 million compared to SEK 17.27 million a year ago. Basic loss per share from continuing operations was SEK 0.67.
For the six months, sales was SEK 0.057 million compared to SEK 1.39 million a year ago. Net loss was SEK 31.18 million compared to SEK 31.51 million a year ago.